These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12378397)

  • 1. Stent coating: a new approach in interventional cardiology.
    Wieneke H; Sawitowski T; Wnendt S; Fischer A; Dirsch O; Karoussos IA; Erbel R
    Herz; 2002 Sep; 27(6):518-26. PubMed ID: 12378397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Coronary stents. From a simple idea to a medical high-tech device].
    Wieneke H; Böse D; Haude M; Eggebrecht H; Konorza T; Naber C; Erbel R
    Med Klin (Munich); 2005 Aug; 100(8):505-11. PubMed ID: 16096733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of active stent coating.
    Wieneke H; Schmermund A; von Birgelen C; Haude M; Erbel R
    Expert Opin Investig Drugs; 2003 May; 12(5):771-9. PubMed ID: 12720489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis.
    Kollum M; Farb A; Schreiber R; Terfera K; Arab A; Geist A; Haberstroh J; Wnendt S; Virmani R; Hehrlein C
    Catheter Cardiovasc Interv; 2005 Jan; 64(1):85-90. PubMed ID: 15619311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits.
    Wieneke H; Dirsch O; Sawitowski T; Gu YL; Brauer H; Dahmen U; Fischer A; Wnendt S; Erbel R
    Catheter Cardiovasc Interv; 2003 Nov; 60(3):399-407. PubMed ID: 14571494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-eluting stent: the emerging technique for the prevention of restenosis.
    Sheiban I; Carrieri L; Catuzzo B; Destefanis P; Oliaro E; Moretti C; Trevi GP
    Minerva Cardioangiol; 2002 Oct; 50(5):443-53. PubMed ID: 12384626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent.
    Waksman R; Pakala R
    EuroIntervention; 2009 Dec; 5 Suppl F():F36-42. PubMed ID: 22100674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of stent design and coatings on restenosis and thrombosis.
    Hara H; Nakamura M; Palmaz JC; Schwartz RS
    Adv Drug Deliv Rev; 2006 Jun; 58(3):377-86. PubMed ID: 16650911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of stent coating on stent deliverability: direct randomised comparison of drug eluting and bare metal stents using the same stent platform.
    Siminiak T; Link R; Wołoszyn M; Kałmucki P; Baszko A
    Kardiol Pol; 2012; 70(10):998-1002. PubMed ID: 23080088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating.
    Wessely R; Hausleiter J; Michaelis C; Jaschke B; Vogeser M; Milz S; Behnisch B; Schratzenstaller T; Renke-Gluszko M; Stöver M; Wintermantel E; Kastrati A; Schömig A
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):748-53. PubMed ID: 15681298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymer stent coating for prevention of neointimal hyperplasia.
    Billinger M; Buddeberg F; Hubbell JA; Elbert DL; Schaffner T; Mettler D; Windecker S; Meier B; Hess OM
    J Invasive Cardiol; 2006 Sep; 18(9):423-6; discussion 427. PubMed ID: 16954581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [State of treatment of coronary artery disease by drug releasing stents].
    Müller R; Büllesfeld L; Gerckens U; Grube E
    Herz; 2002 Sep; 27(6):508-13. PubMed ID: 12378395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylcholine-coated stents.
    Lewis AL; Stratford PW
    J Long Term Eff Med Implants; 2002; 12(4):231-50. PubMed ID: 12627785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A stent is not just a stent: Stent construction and design do matter in its clinical performance.
    Lau KW; Johan A; Sigwart U; Hung JS
    Singapore Med J; 2004 Jul; 45(7):305-11; quiz 312. PubMed ID: 15221045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis.
    Scheller B; Speck U; Abramjuk C; Bernhardt U; Böhm M; Nickenig G
    Circulation; 2004 Aug; 110(7):810-4. PubMed ID: 15302790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-stent restenosis: the gold standard has changed.
    Chin K
    EuroIntervention; 2011 May; 7 Suppl K():K43-6. PubMed ID: 22027726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of molecular events in coronary restenosis using coated stents: The Mayo Clinic Approach.
    Keelan PC; Miyauchi K; Caplice NM; Ashai KH; Schwartz RS
    Semin Interv Cardiol; 1998; 3(3-4):211-5. PubMed ID: 10406696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.